Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Completed · Phase 1/Phase 2

Conditions studied: Discoid Lupus Erythematosus

In brief

The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.

Key facts

Study ID

NCT00708916

Run by

NYU Langone Health

People needed

8

Starts

2008-06-01

Expected to finish

2010-08-01

Last updated by the study team

2021-03-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of cutaneous discoid lupus by clinical and histopathological exam

You may not qualify if…

• Systemic lupus involving the internal organs
• Systemic vasculitis
• History of other clinically significant disease process
• History of HIV, hepatitis B or C
• Concurrent use of immune modulating therapy
• Evidence of incompletely treated tuberculosis
• Pregnant or lactating female

Where it is running

• New York University Tisch Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.